{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T15:39:38Z","timestamp":1771947578486,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T00:00:00Z","timestamp":1472774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.urolonc.2016.08.016","type":"journal-article","created":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T18:43:10Z","timestamp":1475347390000},"page":"38.e1-38.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan"],"prefix":"10.1016","volume":"35","author":[{"given":"Takashige","family":"Abe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Ishizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Harabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ataru","family":"Sazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tango","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoshige","family":"Akino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Murakumo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiyo","family":"Murai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2016.08.016_bib1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00280-005-0175-4","article-title":"Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy","volume":"58","author":"Shinohara","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.eururo.2015.07.042","article-title":"Single-agent taxane versus taxane-containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma","volume":"69","author":"Sonpavde","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib3","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-010-0074-5","article-title":"A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer","volume":"15","author":"Zaghloul","year":"2010","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib4","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.eururo.2007.02.052","article-title":"Impact of multimodal treatment on survival in patients with metastatic urothelial cancer","volume":"52","author":"Abe","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib5","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.eururo.2008.11.039","article-title":"Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30\/05)","volume":"55","author":"Lehmann","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib6","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1586\/era.09.148","article-title":"Management of patients with advanced bladder cancer following major response to systemic chemotherapy","volume":"9","author":"Yafi","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.urolonc.2016.08.016_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.ju.0000099823.60465.e6","article-title":"Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience","volume":"171","author":"Siefker-Radtke","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib8","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.juro.2013.11.004","article-title":"Outcome of metastasectomy for urothelial carcinoma: a multi-institutional retrospective study in Japan","volume":"191","author":"Abe","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.athoracsur.2011.03.097","article-title":"Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma?","volume":"92","author":"Matsuguma","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.urolonc.2016.08.016_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jjco\/28.8.497","volume":"28","author":"Kuroda","year":"1998","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib11","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1442-2042.2011.02913.x","article-title":"Influence of baseline renal function and dose reduction of nephrotoxic chemotherapeutic agents on the outcome of metastatic urothelial carcinoma: a retrospective study","volume":"19","author":"Maru","year":"2012","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jnci\/djt015","article-title":"Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy","volume":"105","author":"Apolo","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2016.08.016_bib14","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib15","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.juro.2012.10.065","article-title":"Prognostic risk stratification of patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy","volume":"189","author":"Nakagawa","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.genm.2012.11.001","article-title":"Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2500 patients with urothelial carcinoma of the bladder","volume":"9","author":"Otto","year":"2012","journal-title":"Gend Med"},{"key":"10.1016\/j.urolonc.2016.08.016_bib17","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2013.11.040","article-title":"Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients","volume":"66","author":"Kluth","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib18","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.clgc.2013.04.010","article-title":"The impact of gender on outcomes in patients with metastatic urothelial carcinoma","volume":"11","author":"Haines","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2016.08.016_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1464-410X.2011.10283.x","article-title":"Changing patterns of bladder cancer in the USA: evidence of heterogeneous disease","volume":"109","author":"Zhang","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2016.08.016_bib20","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1464-410X.2010.09675.x","article-title":"Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973\u20132005","volume":"107","author":"Raman","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2016.08.016_bib21","first-page":"163","article-title":"Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience","volume":"46","author":"Kikuchi","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0090-4295(02)01529-7","article-title":"Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan","volume":"59","author":"Yang","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.08.016_bib23","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1023\/A:1020597611645","article-title":"Squamous and\/or glandular differentiation in urothelial carcinoma: prevalence and significance in transurethral resections of the bladder","volume":"33","author":"Billis","year":"2001","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib24","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.humpath.2006.11.001","article-title":"Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize","volume":"38","author":"Domanowska","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib25","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.urolonc.2012.04.009","article-title":"Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital","volume":"31","author":"Shah","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0378-4274(90)90161-E","article-title":"Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices","volume":"52","author":"Kameyama","year":"1990","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.urolonc.2016.08.016_bib27","first-page":"855","article-title":"Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II)","volume":"19","author":"Ota","year":"1992","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.urolonc.2016.08.016_bib28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00685546","article-title":"Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S Urological Cancer Study Group","volume":"31","author":"Akaza","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib29","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1349-7006.2011.01909.x","article-title":"Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group","volume":"102","author":"Kitamura","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.urolonc.2016.08.016_bib30","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jjco\/hyw071","article-title":"Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy","volume":"46","author":"Kobayashi","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/MOU.0000000000000329","article-title":"Role of surgical consolidation in metastatic urothelial carcinoma","author":"Abe","year":"2016","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.surg.2014.08.036","article-title":"Laparoscopic versus open liver resection for metastatic colorectal cancer: a metaanalysis of 610 patients","volume":"157","author":"Schiffman","year":"2015","journal-title":"Surgery"},{"key":"10.1016\/j.urolonc.2016.08.016_bib33","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/SLA.0b013e3181f66954","article-title":"Laparoscopic resection of colorectal liver metastases: surgical and long-term oncologic outcome","volume":"252","author":"Kazaryan","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.urolonc.2016.08.016_bib34","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","article-title":"Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract","volume":"27","author":"Bellmunt","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.08.016_bib35","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2016.08.016_bib36","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916302538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916302538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:09:06Z","timestamp":1761041346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143916302538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1078143916302538"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.08.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}